- About Us
- Guidelines
-
The Author ensures that the research has been conducted responsibly and ethically with adherence to all relevant regulations. read more..
- For Authors
- For Reviewer
- Manuscript Guidelines
- Membership
-
- Journals
- Reprints
- e-Books
- Videos
- Indexing
- Contact Us
COVID-19
- Submissions
Abstract
Novel Approaches in Cancer Study
Aptamer Technology in the Targeted Delivery of Doxorubicin
-
Open or Close Sarah E Sheikh1, Clay Marsh2 and Duaa Dakhlallah2*
1University of Leeds, M Sc Biotechnology, UK
2West Virginia University, USA
*Corresponding author: Ajay Dhakal, Clinical Fellow, Department of Medicine, Roswell Park Cancer Institute, University at Buffalo, Elm and Carlton Streets, 14263, Buffalo, New York, USA
Submission: July 31, 2017; Published: September 05, 2017
ISSN:2637-773XVolume1 Issue1
Abstract
Thisreview aims at giving an insight at some of the recent approaches in using the aptamer technology in formulating the chemotherapeutic agent, doxorubicin, so as to achieve its targeted delivery and reduce its non-specific cytotoxicity.
Abbreviations: SELEX: Systematic Evolution Of Ligands By Exponential Enrichment; DOX: Doxorubicin; PSMA: Prostate-Specific Membrane Antigen; EpCAM: Epithelial Cell Adhesion Molecule; NPs: Nanoparticles; SPIONs: Superparamagnetic iron oxide nanoparticles; MRI: Magnetic Resonance Imaging; QDs: Quantum Dots; MUC1: Mucin 1; PSMA: Anti-Prostate Specific Membrane Antigen; TLC: Thermally Cross-Linked
Editor In Chief
.jpg)
Signup for Newsletter
Quick Links
Editorial Board Registrations
Submit your Article
Best Paper of the Volume
Reprints
Refer a Friend
Advertise With UsOur Recent Edition
.jpg)
Top Editors
.jpg)
.bmp)
.jpg)
.png)
.jpg)
.png)
.png)
.png)
Financial Support
Sponsors
Latest e-Books
Latest Video
a Creative Commons Attribution 4.0 International License. Based on a work at www.crimsonpublishers.com.
Best viewed in 
| Above IE 9.0 version